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receiving chemoradiation for oral cavity and oropharynx cancer. This phase 1/2 dose and duration escalation study tested the safety of a daily 60-minute pre-RT infusion of GC4419, a superoxide dismutase mimetic. A maximum tolerated dose was not reached, safety was acceptable (nausea/vomiting and facial paresthesia during infusion appeared GC4419 doseerelated), and doses of 30 and 90 mg/d for the duration of radiation were selected for further study.
Introduction
Oral mucositis (OM) is a common, disruptive, and painful complication of radiation and chemoradiation (CRT) for head and neck squamous cell carcinoma (HNSCC) (1) . Approximately 70% of patients receiving CRT for oral cavity or oropharyngeal cancer (OCC) develop severe OM, defined as grade 3 to 4 by the World Health Organization (WHO) scale (2, 3) . Oral mucositis causes marked pain requiring narcotic analgesics and adversely affects nutrition, hydration, speech, swallowing, quality of life, bacteremia risk, and feeding tube placement and use rates (4, 5) . Severe OM is also associated with radiation treatment breaks, which harms successful tumor management (6) (7) (8) . The financial cost of managing patients with severe OM is substantial and is attributable to increased hospitalization and emergency room use (9, 10) .
Recommended approaches to managing OM are limited to palliation and pain control with topical agents and systemic analgesics (11) (12) (13) (14) (15) (16) (17) (18) (19) . The only approved drug or biological to reduce OM, palifermin, is limited to patients at risk for OM associated with conditioning regimens before stem cell transplant for the treatment of hematologic malignancies (20, 21) .
The pathogenesis of mucositis is a complex sequence of biologic events in which oxidative stress plays a pivotal initiating role (22) . Therapeutic radiation causes radiolytic hydrolysis and the formation of reactive oxygen species, including superoxide anion (O 2 -). Superoxide is extremely reactive, triggering a cascade of signaling pathways in the cells and tissues of the submucosa and resulting in apoptosis of epithelial stem cells, consequent loss of epithelial renewal, atrophy, and mucosal ulceration (23) .
A complement of naturally occurring superoxide dismutase (SOD) enzymes exists to dispose of superoxide (24) . However, large, rapidly produced amounts of superoxide due to therapeutic radiation can overwhelm these native SOD enzymes. GC4419 is a highly stable manganesecontaining macrocyclic complex (molecular weight Z 483), whose activity mimics the native enzymes, selectively removing superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite. An active enantiomer of GC4419 protected mice from lethal total body irradiation (25) and reduced radiation-induced OM in a hamster cheek pouch model in a dose-related fashion (26) . GC4419 had equivalent effects in the same OM model but did not spare tumor from the effects of CRT in multiple preclinical models (Galera Therapeutics, unpublished data). Further, GC4419 protected mice from radiation-induced pulmonary fibrosis (27) .
The present study was done to assess the safety of GC4419 in combination with radiation and concurrent cisplatin for patients with OCC and to assess the potential of GC4419 to reduce severe OM.
Patients and Methods

Patients
Eligible patients had oral cavity or oropharyngeal, stage IIIIVb HNSCC, Eastern Cooperative Oncology Group performance status 2, and a treatment plan that called for standard fractionation intensity modulated radiation therapy (IMRT) with concurrent cisplatin (80-100 mg/m 2 every 3 weeks or 30-40 mg/m 2 weekly). The IMRT plan had to include at least 2 oral mucosal sites (right or left buccal mucosa, right or left ventral/lateral oral tongue, floor of mouth, or soft palate) within the cumulative 50-Gy isodose line. The IMRT plans were centrally reviewed by an independent radiation oncologist to confirm adherence to protocol requirements. Adequate marrow, renal, and hepatic functions were required. Prophylactic percutaneous endoscopic gastrostomy tube placement was allowed at enrollment. Patients were excluded if they had prior induction chemotherapy, significant dietary compromise due to reduced oral/pharyngeal function, or concurrent treatment with nitrates.
The protocol was approved by each institution's institutional review board and was registered at ClinicalTrials .gov. Investigators obtained written informed consent from each participant. Data were anonymized to protect the study subjects' identities.
Treatment and study design
Intensity modulated radiation therapy was administered once daily, Monday-Friday, at 2.0 to 2.2 Gy/d, to a cumulative tumor dose between 60 and 72 Gy. The assigned dose of GC4419 was delivered intravenously in normal saline over 60 minutes, ending within 60 minutes before each radiation fraction. Oral rinses limited to sodium bicarbonate, lidocaine, and antifungal agents were permitted. Other concurrent available or experimental systemic or topical pharmaceuticals or devices, or low-level laser therapy, were excluded. Supportive care per American Society of Clinical Oncology guidelines, including antiemetic drugs for cisplatin, was encouraged.
The study followed a serial cohort dose-escalation design with 3 to 6 patients enrolled per cohort. The first 5 cohorts received GC4419 before each of the first 14 IMRT fractions (over approximately 3 weeks), reflecting the duration of Investigational New Drug Applicationsupporting animal toxicology studies of GC4419. These 5 serial cohorts received 15, 30, 50, 75, or 112 mg of GC4419 per dose. These doses were based on previous results with a single 15-minute infusion administered to healthy human volunteers; the 60-minute infusion duration was chosen because dogs tolerated higher doses administered more slowly (ie, 12.5 mg/kg over 60 minutes vs 5 mg/kg over 15 minutes [Galera Therapeutics, unpublished observation]). On the basis of observed safety results in the first 5 cohorts, the protocol was then amended to allow "duration extension" of GC4419 administered progressively longer during IMRT. Three serial cohorts received 112 mg of GC4419 before IMRT for 4, 5, or 6 weeks. Subsequent review of safety and OM results through these cohorts led to a decision by the sponsor to add 3 cohorts to extend dosing further at reduced doses: 90 mg for 6 or 7 weeks or 30 mg for 7 weeks.
Dose-limiting toxicity (DLT) was defined as follows: grade 3 or 4 nausea or vomiting despite maximal antiemetic therapy; grade 4 anemia; grade 4 thrombocytopenia or grade 3 associated with hemorrhage; grade 4 neutropenia lasting >7 days; grade 3 or 4 febrile neutropenia; or other grade 3þ events (except oral mucositis), judged by the investigator not attributable to IMRT, cisplatin, or complications of HNSCC. For adverse events attributable to IMRT or cisplatin but judged to be exacerbated by the presence of GC4419, dose modification of GC4419 was at the investigator's discretion. For any given patient, DLT required the GC4419 dose to be reduced 1 dose level (ie, from 112 mg to 75 mg). Up to 2 such dose reductions per patient were permitted. Six patients per cohort were enrolled if DLT was observed in 1 of the first 3 patients. The maximum tolerated dose (MTD) of GC4419 was defined as the highest dose and longest schedule at which DLT was observed in >1 patient in a single dose and schedule cohort.
Study assessments and analysis
Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Oral mucositis was assessed by trained investigatorevaluators using WHO criteria, in which grade 0 Z no mucositis; grade 1 Z pain and erythema; grade 2 Z ulceration, able to eat solid food; grade 3 Z ulceration, able to consume only liquids; grade 4 Z ulceration, inability to eat requiring tube or parenteral feeding. Oral mucositis was assessed twice weekly with at least a 48-hour interval between assessments during IMRT and weekly thereafter for up to 8 weeks or until the WHO score was <2. Oral mucositis assessment training and quality control were performed by Clinical Assistance Programs (Framingham, MA) to ensure that (1) all oral assessments were performed in a consistent manner using standardized questions, oral cavity examination technique and order, and data collection; and (2) WHO grade scoring was correctly assigned per assessment findings for all OM assessments. To reduce the variability in assessing a patient's diet, investigatorevaluators were trained to carefully elucidate whether dietary compromise was due to oral pain. If not, and the diet was compromised by confounding factors (eg, dysgeusia, edentulous, nausea, mucus, throat pain, functional dysphagia), the WHO score was determined according to what the patient said he or she could eat absent these confounding factors.
Plasma concentrations of GC4419 and major metabolites were measured, using a validated liquid chromatography/mass spectrometry method, before infusion, at the end of infusion, and 1, 2, 4, and 6 to 8 hours after infusion with 2 dosing cycles: week 1/day 2, and day 3 during the last week of the infusion schedule.
Tumor status was assessed by clinical examination at the end of IMRT and 3, 6, 9, and 12 months thereafter. Standard-of-care imaging (computed tomography, positron emission tomography, or magnetic resonance imaging) was done before and 3 and 12 months after IMRT. After completion of the 12-month assessment, study follow-up ended.
Statistical analysis of clinical endpoints was descriptive. Severe OM incidence, time to onset, and duration were tabulated. Patients who never developed OM grade >2 had values of 0 days and >50 days imputed for duration and onset, respectively, of severe OM. Phamacokinetics were analyzed by noncompartmental analysis using the software program Phoenix (WinNonlin Professional version 6.4; PharSight, Mountain View, CA).
Results
Nine US centers enrolled 46 patients between August 2013 and June 2015. Patient characteristics are summarized in Table 1 . Forty-three patients completed OM assessments and were considered evaluable for OM; 44 completed tumor follow-up through 1 year after IMRT and were evaluable for tumor endpoints (Table 2) .
Safety
Initial cohorts received GC4419 for the first 14 days of IMRT at 15 mg (nZ4), 30 mg (nZ3), 50 mg (nZ4), 75 mg (nZ3), or 112 mg (nZ6). In these 5 cohorts, 1 toxicity eventdgrade 3 nausea occurring at 112 mgdwas considered potentially drug-related and therefore dose limiting.
Ten of the 20 patients in these 5 cohorts completed treatment with no severe OM (Fig. 1) . On the basis of the favorable tolerability profile of GC4419 in these cohorts, GC4419 dosing duration was extended by protocol amendment, initially in 3 serial cohorts at 112 mgd20 doses/4 weeks, 25 doses/5 weeks, or 30 doses/6 weeks (nZ3 each). In these 3 cohorts, one patient in the 112 mg/ 6 weeks cohort had grade 3 nausea, which was considered dose limiting. Because no single cohort had >1 patient with DLT, the MTD was not considered exceeded. However, to reduce the potential risk of nausea, the GC4419 dose was lowered in the next 2 additional cohorts, to 90 mg for 30 doses/6 weeks (nZ4), and then 35 doses/7 weeks (nZ6). Concurrently, another cohort received 30 mg for 35 doses/ 7 weeks (nZ4).
Of 46 patients, 41 (89%) received all planned GC4419 infusions. Five patients, all at 112 mg, stopped GC4419 early for adverse events (nZ2) or patient request (nZ3), receiving 2 of 14, 3 of 14, 9 of 14, 10 of 30, or 26 of 30 infusions. One additional patient (112 mg Â 30 doses) had a permanent reduction to 75 mg for the last 6 doses because of grade 3 nausea; the other 40 received their full doses. The median total radiation therapy dose was 70 Gy (<10 Gy for 2 early-withdrawing patients, 81.3 Gy for 1 patient, 66-70 Gy for all others). Radiation therapy breaks of 5 or more consecutive fractions occurred in 3 of 46 patients (6.5%) (attributed to grade 3 nausea; respiratory failure unrelated to GC4419; patient noncompliance). A total of 9 patients (1 at 15 mg of GC4419, 2 at 30 mg, 3 at 90 mg, 3 at 112 mg), all receiving every-3-week platinum, had their platinum doses reduced by 20% to 60% for the second and/or third scheduled dose, at the discretion of the treating investigator, because of adverse events attributed to cisplatin. Four of the 9 patients received the full schedule of Overall, adverse events, the most common of which were cytopenias, nausea, fatigue, constipation, dysgeusia, and dry mouth, were considered attributable to IMRT/ cisplatin, complications of HNSCC, or other concomitant conditions. Although dose escalation of GC4419 was curtailed before reaching a formal MTD, grade 3 nausea or vomiting was more frequent at higher GC4419 doses (Table 3) , as was transient, infusion-related grade 1 facial paresthesia that spontaneously resolved shortly after the infusion and did not limit dosing. 
OM efficacy
For patients who received 30 or 90 mg over the full 6 to 7 weeks of CRT, the cumulative incidence of severe OM was 29% (4 of 14) through 6 weeks of RT (60 Gy), and 50% (7 of 14) at any time, with a median time to onset >50 days, and a median duration of 2.5 days (Fig. 1 , Table 4 ). In contrast, in the initial 5 cohorts, GC4419 for 3 weeks was not as effective in reducing cumulative severe OM through 60 Gy (incidence 40% and duration 4.5 days). For patients in the intermediate treatment group, cumulative incidence at 60 Gy was 44%, at any time 67%, median onset 43 days, and duration 18 days. Duration of all grades of OM seemed to be shorter as GC4419 administration was extended further in the IMRT treatment period (Fig. 2) .
Pharmacokinetics
Peak concentration and area under the concentration time profile were approximately dose-proportional for GC4419 in plasma (data not shown). The terminal elimination halflife was approximately 2 hours, with minimal accumulation upon repeated dosing. There were 2 primary metabolites: the major metabolite GC4520/parent GC4419 ratio was approximately 10% at all dose levels, and the minor metabolite GC4570/GC4419 ratio was <0.2% (data not shown).
Tumor outcomes
Of 46 patients, 44 were evaluable for the 1-year tumor outcome analysis (2 patients withdrew consent for followup; Table 5 ). Per study design, posteradiation therapy follow-up was completed through 12 months for all 44 patients. Three patients died during the follow-up phase: 2 patients with oropharyngeal cancer died of noncancer causes without evidence of progression, and 1 patient with oropharyngeal cancer (human papillomavirus [HPV] negative) died from locoregional and distant recurrence at 6 months. Two additional patients with oropharyngeal cancer (25) 1 (14) 1 (25) 0 2 (50) 3 (50) 5 (50) 5 (63) 1 (33) 1 (33) 4 (100) (16) 1 (10) 2 (25) 0 1 (33) 1 (25) 4 (22) Nausea (any grade)
4 (100) 2 (67) 4 (100) 6 (86) 4 (100) 2 (67) 3 (75) 6 (100) 9 (90) 6 (75) 2 (67) 3 (100) 4 (100) Abbreviation as in Table 1 .
Results for the 14 patients receiving 30 or 90 mg for 6-7 weeks are compared with those in the initial dose escalation phase (nZ20), the intermediate schedule (nZ9), and representative historical controls. Patients who never developed OM of grade >2 had values of 0 days and >50 days imputed for duration and onset, respectively, of severe (grade 3-4) OM.
had locoregional progression at month 12 (1 HPV positive and 1 HPV unknown), and 3 patients had distant metastases at month 12. One of the 5 patients who experienced recurrence was in the full-dose cohort (90 mg Â 35 doses). None of the 5 patients who experienced recurrence required cisplatin dose reduction. Two of the 5 patients received 2 full doses of cisplatin 100 mg/m 2 but missed the last every-3-weeks dose of cisplatin, 1 owing to patient noncompliance and 1 owing to "administrative reasons."
Discussion
In this study we found it feasible to add the SOD mimetic GC4419 to IMRT and cisplatin. Observed safety was acceptable at all dose and duration schedules studied. Delivery of planned CRT was not compromised in the presence of GC4419. Grade 3 nausea and vomiting were more frequent at the highest dose (112 mg). Because of this, and a low threshold for additional toxicity in this patient population, GC4419 dose escalation was curtailed before reaching the study-defined MTD. The most common GC4419-associated adverse eventdmild paresthesiadis similar to reports with sublingual nitroglycerine (28) and is likely due to potentiation of nitric oxide (NO) by GC4419, as has previously been reported to occur with this class of compounds (29) . Superoxide reacts rapidly with NO to remove it, and abruptly reducing the amount of superoxide present would be expected to potentiate NO's effects.
The anticipated incidence, duration, and time to onset of severe OM in this study were favorable compared with historical controls (Table 4) . These controls included the placebo arms of 2 published studies of palifermin (2, 3) and unpublished results known to one of the authors (Sonis) from control arms of multiple prospective OM studies. The unpublished historical controls are not case-matched with the present study, and stage and HPV status are not available. The unpublished experience was limited to patients with oral cavity or oropharyngeal primaries, postoperative and definitive, who received IMRT plus concurrent cisplatin (every 3 weeks or weekly). However, for all of these published and unpublished historical data, mucositis was assessed at sites receiving >50 Gy by the same OM assessment criteria (trained assessors, assessment method, assessment interval, WHO scale) as in the present trial. Although conclusions from historical, cross-study comparisons must be limited, the present results are sufficiently encouraging to warrant more rigorous assessment in a prospective controlled trial.
Oral mucositis results were best for the cohorts that received 30 or 90 mg of GC4419 for 6 to 7 weeks, consistent with expectations that GC4419 should be administered throughout the entire IMRT course to remove superoxide produced with each IMRT fraction. Patients receiving as little as 30 mg of GC4419 had little severe OM (Fig. 1) . Further, OM results through 6 weeks/60 Gy are of interest because this is a common landmark expected to be reached in IMRT of all patients with locally advanced HNSCC.
Although most of our patients developed OM of WHO grade !2, consistent with prior reports (4), severe (WHO grade 3-4) OM is arguably more relevant to clinical benefit. Reducing severe OM should decrease the substantial day- Fig. 2 . Duration of all grades of oral mucositis decreased with longer GC4419 dosing. Each vertical set of bars represents oral mucositis duration by grade for an individual subject. Data are presented by the 3 dosing duration groups (14 doses/ 3 weeks; 4-5þ weeks; or 6-7 weeks) and arranged to increase from left to right for each subgroup for viewing clarity. Abbreviations: DM Z distant metastases; LRC Z locoregional control; OS Z overall survival; PFS Z progression-free survival.
Values are number (percentage). Locoregional control was defined as alive without receiving alternate therapy and without locoregional progression. Two patients who died of noncancer causes were censored from the LRC and DM-free metrics, making the nZ42 for those endpoints.
to-day burden of OM overall (5) . As a result, increased resource usage estimated to cost approximately $18,000 per patient (10) could be reduced. A further question is whether patients' subjective reports of mouth and throat soreness correspond to the WHO score, a relationship that held for palifermin's effects on OM in patients receiving total body irradiation/high-dose chemotherapy and hematopoietic stem cell transplant (30) but not in the trials of that drug in HNSCC patients (2, 3) .
Of equal importance, IMRT treatment breaks are associated with compromised tumor outcomes in HNSCC (7, 8) . That only 3 of 46 patients (6.5%) in this study had radiation therapy breaks of 5 or more consecutive fractions is promising. Treatment breaks of this duration were reported in 15% of both control and experimental patients in the 2 palifermin studies to reduce OM in HNSCC (2, 3), which used 3-field conformal radiation, and 15.1% of patients receiving IMRT/platinum and 26.9% receiving IMRT/cetuximab in the Radiation Therapy Oncology Group 0522 trial (31) .
For cancer supportive care agents, a major concern is that they not compromise or antagonize the efficacy of the underlying antitumor regimen. In the present study tumor outcomes at 1 year did not seem unfavorable compared with contemporary expectations (31), but conclusions are limited owing to the small sample size and lack of a placebo arm for control.
On a mechanistic basis, GC4419 is expected not to antagonize, but instead potentially enhance, tumor radiation response. Normal and cancer cells metabolize reactive oxygen species differently. Specifically, normal cells tend to be more sensitive to elevations in superoxide anion but more tolerant of increases in hydrogen peroxide flux. They utilize redox protective enzyme systems to convert superoxide into water and molecular oxygen, removing it rapidly to prevent normal tissue damage. Although these same enzyme systems are typically active in cancer cells, moderate elevations in superoxide actually serve to promote tumor growth, but significant increases in hydrogen peroxide flux are apparently less well tolerated than for normal cells (32) . Thus, therapeutic radiation, by increasing superoxide, can overwhelm the SOD enzyme system and initiate normal tissue toxicity such as OM. GC4419 can convert this excess superoxide into hydrogen peroxide, which is less toxic to normal tissue, while simultaneously maintaining or even increasing antitumor efficacy. Consistent with this are nonclinical data demonstrating synergy, especially between GC4419 and higher dose-fraction RT regimens (27) , as are becoming used in stereotactic body radiation therapy.
To our knowledge this is the first clinical trial of a selective SOD mimetic to reduce radiation therapyeinduced severe OM. Results in animal models of radiation OM have been reported for a manganese SOD (33) , for nonselective oxygen radical scavengers (34) , and for manganese porphyrins that mimic both SOD and catalase (35) . None of these, however, has been tested in a clinical study of OM. A marketed bovine-sourced copper-zinc SOD was also tested in a small study of head and neck cancer patients for treatment of radiation toxicities in head and neck cancer patients (36) , but that product was subsequently withdrawn from all markets for safety reasons.
The promising OM results of this study, along with a comparative assessment of the contribution of GC4419 to the toxicity and tumor control outcomes of CRT, must be confirmed in a larger randomized, placebo-controlled setting. To that end, doses of 30 and 90 mg/d administered throughout CRT were selected for the randomized, double-blind, placebo-controlled GC4419 phase 2b trial in progress. Tumor follow-up will extend through 24 months after IMRT in that trial.
